Neurocrine Biosciences, Inc.
Darin Lippoldt (Chief Legal Officer) reports NBIX insider transactions
About this filing
Neurocrine Biosciences, Inc. (NBIX) filed Form 4 (insider transaction) with the SEC on Sep 15, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Darin Lippoldt · Chief Legal Officer
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | A · grantFootnotes F1 | +4,483 | $0.00 | $0.00 | 59,212 | Direct |
| Sep 11, 2026 | F · tax withholdingFootnotes F2 | −2,419 | $156.22 | $377,896.18 | 56,793 | Direct |
Footnotes
- F1 The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
- F2 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
More NBIX filings
- 144
Filed Oct 30, 2026
- SC 13G
Filed Oct 30, 2026
- SC 13G/A
Filed Oct 15, 2026
- 3
Filed Oct 7, 2026
- 8-K
Filed Sep 28, 2026
- 4
Filed Sep 15, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.